Schizophrenia News and Research

Latest Schizophrenia News and Research

Slitrk5 gene linked to development of OCD-like behaviors

Researchers at the Ansary Stem Cell Institute and the Department of Psychiatry at Weill Cornell Medical College discovered that mice missing a single gene developed repetitive obsessive-compulsive-like behaviors. The genetically altered mice, which behaved much like people with a certain type of obsessive-compulsive disorder (OCD), could help scientists design new therapies for this debilitating condition.

27 Apr 2010

New discovery links Slitrk5 gene to development of OCD-like behaviors

27 Apr 2010

A first step in the long road to health reform

Australia provides good health care to the majority of its citizens most of the time and compares well with like countries. The capacity for illness to destroy families financially, seen in the US and in many less economically advanced countries where governments make small or no contributions to the cost of health care, is much diminished by Medicare, public hospitals and subsidised pharmaceuticals.

27 Apr 2010

Researchers take major step to predict adverse drug reactions using genetic information

In a new study, researchers at Mount Sinai School of Medicine have taken a major step toward the ability to predict adverse drug reactions, using genetic, cellular, and clinical information to learn why some medicines cause heart arrhythmias in patients. Published in the April 20 issue of the journal Science Signaling, the new framework described in the study could potentially be applied to the study of medications that treat other diseases and disorders such as epilepsy and autism.

23 Apr 2010

Researchers receive grant to help people living with mental illness tackle tobacco dependence

Researchers at The University of Nottingham have won government funding to improve the services which help people living with serious mental illness to tackle their tobacco dependence.

22 Apr 2010

Titan Pharmaceuticals expects approximately $1.6M as royalty on first-quarter sales of Fanapt

Titan Pharmaceuticals, Inc. today confirmed that the company expects to receive a payment of approximately $1.6 million by May 15, 2010 as the royalty on the first quarter 2010 sales of Fanapt™ (iloperidone), a drug for the treatment of schizophrenia launched in the US by Novartis Pharma AG in January 2010.

22 Apr 2010

Understanding genetic causes of mental retardation

This remarkable publication focuses on the importance of genetics in mental retardation, investigating the extent to which molecular diagnostic capability and the understanding of genetic causes have improved over recent years. As a result, clinical evaluation and diagnostic laboratory practice are now undergoing an unprecedented period of change.

22 Apr 2010

Study analyzes effects of untimely and sudden parental death on childhood development

Losing a parent to suicide makes children more likely to die by suicide themselves and increases their risk of developing a range of major psychiatric disorders, according to a study led by Johns Hopkins Children's Center that is believed to be the largest one to date on the subject.

22 Apr 2010

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Abbott today announced financial results for the first quarter ended March 31, 2010.

21 Apr 2010

Drugmakers raised prices last year in anticipation of new health law, Eli Lilly reports financial hit

"Drug companies sharply raised prices last year, ahead of increased rebates they must pay to Medicaid and other expenses tied to the federal health overhaul passed last month. Prices for brand-name pharmaceuticals rose 9.1% last year, the biggest increase in at least a decade, according to pharmacy-benefit manager Express Scripts Inc."

21 Apr 2010

Systems biologists integrate new genetic framework to help predict adverse drug reactions

In a major step toward predicting adverse drug reactions, systems biologists at Mount Sinai School of Medicine in New York City have integrated genetic, cellular and clinical information to find out why certain medicines can trigger fatal heart arrhythmias.

21 Apr 2010

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.07 in the fourth quarter of fiscal 2010.

21 Apr 2010

Cannabis users are at risk for developing anxiety and mood disorders: CAMH study

Research has shown possible links between cannabis use and the onset of Schizophrenia, but a new study from the Centre for Addiction and Mental Health shows that people who use cannabis may also be at risk for developing anxiety and mood disorders.

21 Apr 2010

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Individuals involved in rescue, recovery, demolition, and clean-up after the World Trade Center (WTC) disaster on September 11, 2001, were exposed to a complex mixture of airborne smoke, dust, combustion gases, acid mists, and metal fumes. The impact of this exposure on responders' upper and lower respiratory function has been well documented, but little is known about its impact on their sensitivity to odor and irritants.

19 Apr 2010

RUCDR is poised to become a world leader in human disease and genome studies

Despite the continuing, crippling effects of a nationwide recession, a genetics research laboratory on Rutgers' Busch Campus is experiencing an economic boom.

16 Apr 2010

Study on primary cilia formation may lead to new therapies for ciliopathies

A team of scientists at the University of California, San Diego School of Medicine have identified a network of genes that initiate and manage cilia formation. Although scientists have known about cilia for decades, only recently have they discovered their role in disease. This new discovery, which may lead to new therapies for ciliopathies, will appear in the April 15 edition of Nature.

16 Apr 2010

Working memory maintenance linked with synchronisation of neurons

A research project of the Neuroscience Center of the University of Helsinki sheds light on the neuronal mechanisms sustaining memory traces of visual stimuli in the human brain. The results show that the maintenance of working memory is associated with synchronisation of neurons, which facilitates communication between different parts of the brain. On the basis of interaction between the brain areas, it was even possible to predict the subject's individual working memory capacity.

15 Apr 2010

Alkermes submits VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) to the U.S. Food and Drug Administration (FDA) for approval as a treatment for opioid dependence. The company requested a priority review for its sNDA and if granted by the FDA, it would mean a six month review timeline.

13 Apr 2010

Article One Partners concludes AUTO Patent Studies

Article One Partners, the world's largest patent validation firm, today announced the conclusion of two Patent Studies conducted on behalf of a top global automaker, for which $30,000 has been awarded to two Advisors.

13 Apr 2010

Health care experts brand plan for a “Big Australia” as disaster waiting to happen

Increased immigration rates are set to make Australia’s population hit 36 million by the year 2050 according to Federal Government estimates. This would be a huge leap from the present 22,300,000 people that the nation has today. The added population is being seen as a necessity to ensure economical survival for the country.

13 Apr 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

Slitrk5 gene linked to development of OCD-like behaviors

New discovery links Slitrk5 gene to development of OCD-like behaviors

A first step in the long road to health reform

Researchers take major step to predict adverse drug reactions using genetic information

Researchers receive grant to help people living with mental illness tackle tobacco dependence

Titan Pharmaceuticals expects approximately $1.6M as royalty on first-quarter sales of Fanapt

Understanding genetic causes of mental retardation

Study analyzes effects of untimely and sudden parental death on childhood development

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Drugmakers raised prices last year in anticipation of new health law, Eli Lilly reports financial hit

Systems biologists integrate new genetic framework to help predict adverse drug reactions

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Cannabis users are at risk for developing anxiety and mood disorders: CAMH study

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

RUCDR is poised to become a world leader in human disease and genome studies

Study on primary cilia formation may lead to new therapies for ciliopathies

Working memory maintenance linked with synchronisation of neurons

Alkermes submits VIVITROL sNDA for opioid dependence

Article One Partners concludes AUTO Patent Studies

Health care experts brand plan for a “Big Australia” as disaster waiting to happen

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Schizophrenia News and Research

Latest Schizophrenia News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in